After 12 months, the accumulative relapse rates were eight of 18 (44.4 percent) and nine of 18 (50.0 percent). Derko, and K. Horon, Royal Alexandra Hospital, Edmonton, Alta. ; M.K. The median length of the ICU stay was 9 days (interquartile range, 5 to 15) in the ranitidine group and 9 days (interquartile range, 5 to 17) in the sucralfate group (P = 0.27). Prophylaxis against stress ulcers has traditionally been recommended for the prevention of upper gastrointestinal bleeding in critically ill patients.Randomized trials of prophylaxis against stress ulcers, as compared with no prophylaxis, indicate that histamine HThe need to evaluate patients at highest risk for both bleeding and pneumoniaFrom October 1992 to May 1996, we screened consecutive patients admitted to 16 participating intensive care units (ICUs) to identify adults who were projected to require mechanical ventilation for at least 48 hours. Demographic and base-line physiologic characteristics were similar in the two groups (No patient received active drug instead of the assigned placebo, or vice versa. Clinically important gastrointestinal bleeding developed in 10 of 596 (1.7 percent) of the patients receiving ranitidine, as compared with 23 of 604 (3.8 percent) of those receiving sucralfate (relative risk, 0.44; 95 percent confidence interval, 0.21 to 0.92; P = 0.02). One patient in the ranitidine group had myalgia and one reported headache in phase I. There are conflicting data on the effect of histamine HIn a multicenter, randomized, blinded, placebo-controlled trial, we compared sucralfate with the HThe patients in the two groups had similar base-line characteristics. Thomas Todd, Thomas Noseworthy, Timothy Winton, and Michael Tryba for their support and advice.From McMaster University, Hamilton, Ont. On utilise la ranitidine pour réduire la quantité d'acide sécrétée par l'estomac afin de réduire les douleurs des ulcères ou les brûlures d'estomac ou pour faciliter la guérison des ulcères. ; D. Roberts, T. Ostrusniuk, and J. Studney, Winnipeg Health Sciences Center, Winnipeg, Man. (G.W.) ; T. Winton, D. Foster, D. Baptiste, M. Steinberg, and M. Lee, Toronto Hospital, General Division, Toronto; G. Darling, M. Culham, and V. Bobiwash, Wellesley Hospital, Toronto; M. Lefcoe (study radiologist), D. McCormack (study bronchoscopist), L. McCarthy, and C. Gawlik, London Health Sciences Center (Victoria Campus), London, Ont. This site needs JavaScript to work properly. ; A. Taite and P. Newman, Kingston General Hospital, Kingston, Ont. (S.P. Sucralfate (sukralfat) adalah obat untuk mengatasi tukak pada lambung dan usus halus.. Sucralfate bekerja dengan cara membentuk lapisan pelindung pada tukak untuk melindunginya dari infeksi dan kerusakan lebih lanjut. Scott and S. Jansen, St. Joseph's Health Center, London, Ont. La disparition des douleurs ne signifie pas que l'ulcère est cicatrisé : la durée du traitement doit être respectée. In conclusion, sucralfate appears to be as effective as ranitidine in the short-term treatment of gastric ulcers and in relapse prophylaxis. Clipboard, Search History, and several other advanced features are temporarily unavailable. Sur ordonnance (Liste II) Composition du médicament RANITIDINE TEVA. This clinical study compared the healing capacities of sucralfate and ranitidine in the treatment of gastric ulcer. Concise summaries and expert physician commentary that busy clinicians need to enhance patient care.The most effective and engaging way for clinicians to learn, improve their practice, and prepare for board exams.NEW! In the ranitidine group, 114 of 596 patients (19.1 percent) had ventilator-associated pneumonia, as compared with 98 of 604 (16.2 percent) in the sucralfate group (relative risk, … Ranitidine versus previous ranitidine, sucralfate versus previous sucralfate and each one versus no treatment showed comparable relapse rates. 1986 Dec 12;111(50):1910-5. doi: 10.1055/s-2008-1068734.Am J Med. Excluded patients were a mean (±SD) of 60.8±15.3 years of age and had a mean APACHE II score of 21.4±7.9.We randomly assigned 1200 patients to the sucralfate or ranitidine group. This finding appears to contrast with the results of a recent meta-analysis, which suggested that the drugs' effect on bleeding was equivalent (relative risk, 0.95;95 percent confidence interval, 0.17 to 5.36)The strengths of our trial include the measures taken to conceal the patients' treatment assignments; the blinding of care givers, research personnel, and analysts; the high rates of compliance; the adjudication of outcomes according to rigorous criteria; and the examination of the relation between prophylaxis and the incidence of ventilator-associated pneumonia defined according to a variety of criteria, given the absence of a well-accepted reference standard. Traitement aigu de l'ulcère peptique . ; S. Salama, Henderson Hospital, Hamilton, Ont. ; and Richard Johnston, M.D., University of Alberta, Edmonton.In addition to the authors, the study investigators and institutions were as follows: B. Plumstead and L. Frighetto, Vancouver General Hospital, Vancouver, B.C. Results of the adjusted analysis were similar (relative risk, 1.14; 95 percent confidence interval, 0.91 to 1.44; P = 0.26).All patients were included in the analysis.